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ROLE OF MACROPHAGES IN ADAPTIVE RESISTANCE TO ANTI-VEGF
THERAPY
Heather J. Dalton, M.D.
Advisory Professor: Anil K. Sood, M.D.
Background: The clinical implementation of therapies targeting the VEGF pathway
in cancer has been limited by acquired resistance; yet, the mechanisms by which
this occurs is unclear. We investigated the role of macrophages in the development
of acquired resistance to anti-VEGF antibody (AVA) therapy.
Materials and Methods: We first established a murine ovarian cancer model of
resistance to anti-VEGF therapy. Using this model we investigated changes in
macrophage infiltration during AVA sensitive and resistant phases. We also
investigated the in vivo effects of macrophage depletion at the emergence of antiVEGF resistance and in upfront combination with AVA therapy. In vitro, we
assessed differences in viability and invasion/migration in AVA sensitive and
resistant macrophages. We also investigated macrophage VEGF receptor
expression in response to AVA therapy. Finally, we performed high throughput
analyses to determine pathways important in modulating macrophage response to
AVA.
Results: We show that macrophages are actively recruited to the tumor
microenvironment, where their accumulation correlates with the emergence of antiVEGF resistance. Importantly, depletion of macrophages at the emergence of antiVEGF resistance halts tumor growth and significantly prolongs survival in murine
models. Additionally, the upfront combination of anti-VEGF therapy with
macrophage depletion is synergistic, decreasing tumor growth in vivo. We found
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downregulation of macrophage VEGFR-1 expression in conjunction with
upregulation of alternative angiogenic and anti-apoptotic pathways at the
emergence of resistance, possibly facilitating escape from VEGF-directed therapies.
Conclusions: After establishing murine ovarian cancer models of anti-VEGF
resistance, we demonstrate a previously unrecognized role for macrophages in
adaptive resistance to anti-VEGF therapy. Depletion of macrophages restores
sensitivity to AVA therapy and reduces tumor growth in combination with VEGF
blockade. Collectively, this study highlights macrophages as catalysts in the
development of anti-VEGF resistance and offers strategies to modulate the
influence of macrophages, thus improving the effectiveness of anti-VEGF therapy.
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Background and Introduction
Epithelial ovarian cancer
In 2014, an estimated 14,270 new cases of epithelial ovarian cancer will be
diagnosed, while approximately 21,980 women will die of this disease, making it the
fifth leading cause of cancer death among women and the most lethal gynecological
malignancy (1). Improvements in surgical approaches and the utilization of platinum
and taxane-based cytotoxic agents has resulted in a 1.6 year gain in life expectancy
over the last thirty years (2, 3). Despite these improvements and an initial response
to chemotherapy in up to 80% of patients with advanced disease, the majority of
these women will relapse after first-line treatment and eventually succumb to their
disease (4, 5).
Treatment options following recurrence often depend on the elapsed interval
from when the patient last received platinum-based therapy.

In patients with

platinum-resistant disease (i.e., cancer recurrence or progression within 6 months
after receiving platinum therapy), single-agent chemotherapy is most commonly
recommended. Such agents include docetaxel, topotecan, pegylated liposomal
doxorubicin, gemcitabine, or weekly paclitaxel (6). Response to these second-line
treatments has yielded disappointing results of approximately 20% (7-10).
These findings highlight the need for more efficacious chemotherapy
regimens in both the up-front and recurrent settings. Increasingly, attention has
been focused on targeting the biological pathways that fuel ovarian cancer growth.
One attractive strategy is directed at targeting tumor blood vessel growth, a process
known as anti-angiogenesis therapy (6).
1

Angiogenesis and tumor growth
Angiogenesis is a central hallmark of cancer

and is essential for tumor

growth and metastasis (11). While the mechanisms regulating blood vessel
formation in cancer are complex, the vascular endothelial growth factor (VEGF)
family is known to be a predominate pathway (12). VEGF (VEGF-A) interacts with
the tyrosine receptor kinase, VEGF Receptor-2 (VEGFR-2), and is the central
promoter of tumor angiogenesis (13, 14). VEGF also has known angiocrine and
intracrine functions, where it has been shown to modulate cancer cell survival (15,
16). Cofactors Neuropilin 1 and 2 (NRP1, NRP2), potentiate the activity of VEGFR2 and can also signal independently. VEGF can exist as both soluble and matrixbound isoforms, with the former controlling vessel enlargement and the later
regulating branching morphogenesis (17).
VEGF-C is another member of the VEGF family capable of interaction with
both VEGFR-2 and VEGFR-3. VEGF-C regulates the activation of blood vessel tip
cells (18). VEGFR-3 is essential for blood vessel formation during embryogenesis
and later plays important roles in the regulation of lymphangiogenesis (19).
Importantly, VEGFR-3 can augment VEGF-induced angiogenesis and sustains
blood vessel growth, even in the presence of VEGFR-2 inhibitors (19).
VEGF Receptor-1 (VEGFR-1) interacts with VEGF-B and also binds to VEGF
with high affinity. VEGFR-1 may serve as an alternative receptor for VEGF, thereby
regulating the amount of VEGF available to activate VEGFR-2. In support of this
concept, loss of VEGFR-1 results in vessel overgrowth (20). VEGFR-1 also plays
roles in the pathologic angiogenesis seen in tumor growth. Tumor cells are known
2

to express VEGFR-1, which may facilitate VEGF interaction through autocrine
mechanisms (21). Additionally, VEGFR-1 is capable of inducing the growth of
VEGFR-1-expressing tumor cells (22).
Placental growth factor (PlGF) is another member of the VEGF family, acting
as a cytokine to stimulate angiogenesis.

PlGF activates bone-marrow derived

myeloid cells and endothelial progenitors, in addition to directly activating tumor
cells (20). PlGF can also directly bind to VEGFR-1 (17).
In addition to the VEGF family, other factors make substantial contributions
to aberrant angiogenesis, including the notch-deltalike ligand 4 (Dll4) pathway.
Vascular endothelial cells express the notch 1 and 4 receptors, as well as the
ligands jagged 1, Dll1, and Dll4. This pathway has also been implicated in the
establishment of a perivascular niche for colon cancer stem cells by endothelial
cells (23). Notch-Dll4 signaling is critical for embryonic angiogenesis, as its
haploinsufficiency in knock-out experiments is lethal (24).

Dll4 is upreglated in

tumor vasculature, in part by VEGF, which may allow it to serve as a negative
feedback mechanism for sustained angiogenesis (25).
The angiopoietin-Tie pathway also plays roles in tumor angiogenesis. Tie-1
and Tie-2 are tyrosine kinases predominantly found on vascular endothelium and
serve as receptors for the ligands, ANG-1, ANG-2, and ANG-4.

ANG-1 works

through Tie-2 to regulate endothelial cell quiescence and vessel tightness (26). In
response to angiogenic stimuli, sprouting endothelial cells release ANG-2, which
antagonizes the activity of ANG-1 and Tie-2 and increases vascular permeability
and vessel sprouting (27). In cooperation with VEGF, ANG-2 works to stabilize and
3

mature new capillaries (25). ANG-2 is also released by tumor cells, resulting in the
recruitment of pro-angiogenic Tie-2 expressing monocytes and macrophages (28).
Therapies targeting angiogenic pathways in cancer
Given the importance of angiogenesis in tumor growth, therapies targeting
VEGF and other pro-angiogenic pathways have been the subject of intense
investigation. The first targeted anti-angiogenic agent was approved by the Food
and Drug Administration (FDA) in 2004. Bevacizumab, a humanized monoclonal
VEGF antibody, demonstrated activity in metastatic colorectal cancer in
combination with standard chemotherapy, resulting in a survival benefit in a
randomized phase 3 trial (29). Bevacizumab was subsequently approved by the
FDA for the treatment of advanced non-small cell lung cancer, renal cell carcinoma,
and recurrent glioblastoma (30). This agent was also initially approved for the
treatment of metastatic breast cancer; however, this approval was withdrawn in
2011 after failing to improve overall survival. Bevacizumab has also been use in
both the up-front and recurrent ovarian cancer settings, with improvement in
progression-free survival, which may be reasonable endpoint given the prolonged
survival of these patients following progression (31). In the setting of recurrent
disease, historical response rates to bevacizumab as monotherapy range from 16%
to 21%. Combination with other chemotherapeutic agents increases response rates
to 24-31% (32).
Several small-molecule receptor-tyrosine-kinase inhibitors (RKTIs) have
been approved as targeted anti-angiogenic agents. Sunitinib targets multiple
tyrosine kinases, including VEGFR-1, VEGFR-2, Platelet-derived growth factor
4

receptors (PDGFRs), and macrophage colony stimulating factor receptor (CSF1R),
with demonstrated activity in pancreatic neuroendocrine tumors, advanced renal cell
carcinoma, and gastrointestinal stromal tumors (25, 33). Sorafenib is FDA-approved
for renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer
and inhibits VEGFR-1, VEGFR-2, and VEGFR-3, as well as PDGFR-β (34).
Alternative methods to target VEGF include aflibercept, a fusion protein composed
of the VEGFR-1 and VEGFR-2 extracellular domains with high affinity for VEGF-A,
VEGF-B, and PlGF(30). Compounds directed at the ANG-TIE pathway are also in
developm
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These graphs show a 30 year period of ovarian cancer incidence and mortality. On left you can see a
slight decrease in the overall incidence of ovarian cancer. Improvements in surgical approaches and the
utilization of platinum and taxane-based cytotoxic agents has resulted in a 1.6 year gain in life
expectancy over the last thirty years. Despite these improvements and an initial response to
chemotherapy in up to 80% of patients with advanced disease, the majority of these women will relapse
after first-line treatment and eventually succumb to their disease. Thus there is a continued impetus for
new treatment options, including the development of targeted agents.
Angiogenesis is a central hallmark of cancer and is essential for tumor growth and metastasis. While the
mechanisms regulating blood vessel formation in cancer are complex, the vascular endothelial growth
factor (VEGF) family has been found to be a predominate pathway. This Family of glycoproteins and
type III tyrosine kinases and associated molecules are shown on the figure
VEGF (VEGF-A) binds to VEGFR-1 and VEGFR2
Endothelial cell proliferation
Migration, invasion, and survival
VEGF-B binds to VEGFR1
Blood vessel survival factor
VEGF-C binds to VEGFR2 and VEGFR3
Angiogenesis, lymphangiogenesis and vascular permeability
VEGF-D binds to VEGFR2 and VEGFR3
Angiogenesis, lymphangiogenesis and vascular permeability

Bevacizumab, a humanized monoclonal VEGF antibody, demonstrated activity in metastatic
colorectal cancer in combination with standard chemotherapy, resulting in a survival benefit in a
randomized phase 3 trial. Bevacizumab was subsequently approved by the FDA for the
treatment of advanced non-small cell lung cancer, renal cell carcinoma, and recurrent
glioblastoma. This agent was also initially approved for the treatment of metastatic breast
cancer; however, this approval was withdrawn in 2011 after failing to improve overall survival.
Bevacizumab has also been use in both the up-front and recurrent ovarian cancer settings, with
improvement in progression-free survival
Several small-molecule receptor-tyrosine-kinase inhibitors (RKTIs) have been approved as
targeted anti-angiogenic agents. Sunitinib targets multiple tyrosine kinases, including VEGFR-1,
VEGFR-2, Platelet-derived growth factor receptors (PDGFRs), and macrophage colony
stimulating factor receptor (CSF1R), with demonstrated activity in pancreatic neuroendocrine
tumors, advanced renal cell carcinoma, and gastrointestinal stromal tumors (25, 33). Sorafenib
is FDA-approved for renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid
cancer and inhibits VEGFR-1, VEGFR-2, and VEGFR-3, as well as PDGFR-b (34). Alternative
methods to target VEGF include aflibercept, a fusion protein composed of the VEGFR-1 and
VEGFR-2 extracellular domains with high affinity for VEGF-A, VEGF-B, and PlGF(30)
As angiogenesis is a critical component for tumor growth and VEGF is constitutively overexpressed in
numerous cancers, therapies targeting this pathway were eagerly anticipated additions to standard

ent.
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In ovarian cancer, numerous agents targeting angiogenesis are being
investigated. AMG 386 is an inhibitor of ANG-1 and ANG-2 with activity in recurrent
ovarian cancer currently in clinical trials. Others include the multi-kinase inhibitor,
cediranib, which targets VEGFR-1, -2, and -3, PDGFR-α/β, FGFR-1, and c-kit;
and nintedanib, directed against VEGFR-1, -2, and -3, PDGFR-α/β, FGFR-1, -2,
and -3, as well as the sarcoma viral oncogene homolog (Src) family. Pazopanib,
targeting VEGFR-1, -2, and -3, PDGFR-α/β, FGFR-1 and -3, and c-kit; and
sorafenib are also being evaluated (5).
Adaptive resistance to anti-angiogenic therapies
As angiogenesis is a critical component for tumor growth and VEGF is constitutively
overexpressed in numerous cancers, therapies targeting this pathway were eagerly
anticipated additions to standard chemotherapy (35, 36). Yet, clinical survival
benefits have been modest, usually measured in months (25).

Resistance to

angiogenic blockade often develops (17). Rebound tumor growth, along with rapid
revascularization following termination of anti-angiogenic therapies, has been
demonstrated (37, 38). Intriguingly, collapse of survival curves and clinical benefit
is observed following cessation of agents such as bevacizumab (39-41). Several
mechanisms for this phenomenon have been proposed. VEGF blockade produces
hypoxia at the tumor level, which can increase the production of alternative proangiogenic factors. Tumors may also utilize other methods of vascularization, such
as vasculogenic mimicry or vessel co-option. Further, stromal components of the
tumor microenvironment, including macrophages, may offer alternative angiogenic
avenues in the setting of VEGF blockade (17). T-helper type 17 cells, with their
7

major cytokine IL-17, have been implicated in such mechanisms of resistance to
anti-VEGF therapy through induction of G-CSF and recruitment of immature
myeloid cells, including macrophages (42)
Characterization of Macrophages
Macrophages arise from differentiated monocytes, which enter the circulation after
development from a myeloid progenitor in the bone-marrow. The transcriptome of
macrophages is complex, allowing them to serve diverse and often tissue-specific
functions (43). Historically, macrophages have been described as classically
activated M1 or alternatively activated M2 phenotypes. These phenotypes are now
thought to represent extremes in a continuum of macrophage activation, and have
been reversed, highlighting their plasticity in response to environmental signals (4446).
Pro-inflammatory macrophages, or the classical M1 phenotype, react to
STAT1 signaling pathways through response to INF-γ and activation of Toll-like
receptors (TLRs) (47). TNFα, IL-1β, IL-6, IL-12, type 1 INF, as well as reactive
oxygen species contribute to the pro-inflammatory properties of this phenotype
(Table 1) (48). Arginine metabolism leads to inducible nitric oxide production. Major
histocompatibility complex II (MHC II) is elevated, allowing interactions with Th1
cells (49). STAT3 and STAT6 are activated by IL-4 and IL-13, with subsequent
transcription of characteristic genes of pro-angiogenic macrophages,

(50). The

arginase pathway results in the production of ornithine and polyamines (51).
Characteristic features are seen in Table 1.
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Table 1. Associated chemokines and cytokines of macrophage phenotypes.
Pro-inflammatory
Pro-angiogenic
Macrophages
Macrophages
CCL3, CCL4, CCL5,
CCL2, CCL16, CCL17,
Cytokines and
CCL8, CXCL9, CXCL10,
CCL18, CCL22, CCL24,
Chemokines
CXCL11
CXCL1, CXCL2
MMPs, IL-8, VEGF-A,
TNF-α, IL-1β, IL-6, IL-12,
Other factors
VEGF-C, VEGF-D, FGFINF, Reactive O2 species
2, ARG-1, Wnt5a, Wnt7b
CCR7, CD14, CD16,
CD14, CD23, CD163,
CD32, CD64, CD84,
CXCR1, CXCR2, CXCR4,
Surface Receptors
CD86, MHCII,
CCR2, IL-1Ra, VEGFR-1,
TRL2/TRL4, CSF1-R
VEGFR-2, VEGFR-3,
Tie-2, mannose receptor

Macrophages in tumor angiogenesis
Tumor associated macrophages (TAMs) are abundant in established tumors,
where they were initially thought to be tumoricidal. Contemporary evidence,
however, demonstrates a much more sinister purpose. Macrophage infiltration is
associated with increased tumor invasion, migration and poor clinical prognosis in
80% of solid tumors (46, 52). Tumor and stromal cells produce numerous factors
that actively recruit macrophages to the microenvironment, including VEGF (47, 53).
Tumors are also rich in hypoxia, a known macrophage chemoattractant. While most
macrophages influxing into the cancerous microenvironment are believed to
originate from the circulating monocyte population and are, therefore, bone-marrow
derived, recent studies demonstrate the ability of resident tissue macrophages to
proliferate. Proliferation of resident tissue macrophages has been described as the
dominant mechanism for the establishment of peritoneal macrophages in the
postnatal period. Specifically, in the context of inflammation, both resident
peritoneal macrophages and recruited bone-marrow derived macrophages have
9

been demonstrated to proliferate in the microenvironment, adding new complexity
our previous understandings of macrophage differentiation (54). This proliferative
ability has recently been linked to the transcription factor Gata6 (55).
Once in the tumor microenvironment, macrophages secrete numerous proangiogenic factors including VEGF-A, VEGF-C, VEGF-D, IL-8, and FGF-2; which
help flip the angiogenic switch regulating the transformation to malignancy (21, 46,
56). Increased capillary density is correlated with TAM infiltration (21).
Macrophages also express VEGFR-1, VEGFR-2, and VEGFR-3, permitting
interaction with ligands of the VEGF family (56, 57). TAMs are transcriptionally
similar to the pro-angiogenic macrophage phenotype, with high levels of IL-8, TGFβ, ARG-1 and the mannose receptor in conjunction with low levels of proinflammatory cytokines (53, 58). In response to hypoxia, macrophages upregulate
HIF-1α and HIF-2α, which facilitate the transcription of genes involved in
angiogenesis (53). Tie2 is also upregulated, enhancing pro-angiogenic polarization.
Response to anti-cancer therapies can be altered by TAMs. Radiotherapy
induces CSF1, leading to recruitment of CSF1R-expressing macrophages and
enhanced tumor regrowth via their associated pro-angiogenic properties, while
CSF1R inhibitors have resulted in improved response to radiation (59). Tumor
regrowth following radiotherapy is linked to macrophage recruitment by CXL12 in
response to hypoxia. Platinum therapy increases pro-angiogenic macrophages in
tumor samples (60). Further, macrophages are associated with the development of
resistance to anti-tumor therapies, including platinum-based chemotherapy and
radiotherapy (59-61). The development of resistance to anti-VEGF therapy has
10

been linked to macrophages, secondary to their ability to activate pro-angiogenic
pathways (62). Macrophages are also directly tied to vascular regrowth following
therapy-induced vascular injury (61).
Mechanisms to target macrophages
Numerous methods of targeting macrophage-driven angiogenesis are
currently being investigated. Bisphosphonates, used clinically for the treatment of
osteoporosis and bony metastases, are one potential approach. Multiple large-scale
studies have demonstrated the reduced risk of breast and colon cancers in patients
receiving bisphosphonates (46, 63). Bisphosphonates reduce bone metastasis in
breast cancer patients, and in those with prostate or renal cell carcinoma and preexisting bone metastasis, result in a trend towards increased survival (64).
Bisphosphonates work by inhibiting of osteoclast activity, which contributes to the
growth of solid tumors by liberating bone marrow-derived growth factors such as
TGF-β and IGF. Importantly, they also have been found to directly induce apoptosis
in TAMS with a resultant decrease in tumor infiltration and associated proangiogenic factors that aid tumor growth and spread. This apoptotic effect is
mediated through the inhibition of farnesyl diphosphate synthase, which prevents
prenylation of small GTPase signaling proteins required for normal cellular function
(65). Bisphosphonate treatment has also significantly reduced angiogenesis in
several murine cancer models (66).
The DNA binding agent, trabectedin, has activity against macrophages.
Treatment with trabectedin reduced TAM infiltration, resulting in significantly
reduced tumor growth and metastasis, as well as decreased angiogenesis (67).
11

These effects are mediated through induction of the extrinsic apoptosis pathway,
with specificity for cells of monocytic lineage. The expression of functional TRAIL
receptors seen on monocytes and TAMs is responsible for this specificity, as
neutrophils and lymphocytes have decoy TRAIL receptors, which impart protection
from the effects of trabectedin (67).
Inhibition of the CSF1 receptor (CSF1R) is also being investigated, as its
ligand, CSF1, is a potent recruiter of macrophages and monocytes and is
unregulated in the tumor microenvironment. In prostate cancer models, the CSF1R
inhibitor, GW2580, reduced tumor regrowth following irradiation and reduced
infiltration of TAMs (68). This selective small kinase inhibitor competitively binds to
CSF1R, thereby preventing CSF-1-dependent macrophage growth (69). Reduced
TAM recruitment and decreased vascular density was seen in breast cancer
models, along with reduced tumor growth in prostate cancer models following
treatment with the small molecule CSF1R kinase inhibitor, PLX3397. Additionally,
treatment with PLX3397 enhanced CD8+ T cell response, resulting in improved
chemosensitivity (70). AC708 is another high-affinity CSF1R inhibitor with
demonstrated activity in breast cancer models currently in clinical development
(work yet unpublished, poster presented at AACR 2013).
PF-04136309, a CCR2 inhibitor, depletes TAMs, reduces metastasis, and
enhances chemosensitivity in pancreatic cancer models (71). Anti-STAT3 agents
offer additional possibilities for macrophage modulation (71). Anti-Ang2 antibodies
produced regression of tumor vasculature and decreased tumor progression in
murine models of pancreatic and breast cancer (62).
12

Macrophage

reprogramming

is

being

explored

through

the

PD-1

(programmed death-1) pathway. This inhibitory factor is secreted by macrophages
in the tumor microenvironment, with a subsequent reduction in CD8+ cytotoxic T cell
activity and induced immune tolerance. In an ovarian cancer model, PD-L1
blockade, in combination with whole tumor antigen vaccination, increased immune
activity and facilitated tumor rejection through stimulation of CD8+ T cells (46, 72).
This tumoricidal macrophage phenotype is achieved through administration of an
agonistic CD40 antibody for “priming,” followed by a “triggering” signal mediated
through toll-like receptors (TLRs). This method of macrophage reprogramming has
produced tumor regression in vivo (73).
Tumor cells express “don’t eat me” signals through expression of CD47.
This surface receptor interacts with signal regulatory protein α (SIRPα) on the
surface of TAMs, inducing a powerful anti-phagocytosis signal. CD47 inhibition
increases the phagocytic capability of macrophages with resultant tumoricidal
response. These anti-CD47 antibody therapies are currently in clinical development
(73).
Macrophage-derived exosomes are also being utilized to achieve targeted
drug delivery to the tumor microenvironment. These endogenous nanovesicles are
capable of transferring biological information between cells. Recently, macrophages
have been broken down into nanovesicles mimicking exosomes, with retention of
plasma membrane proteins, thus maintaining the inherent targeting ability of the
original macrophage. These macrophage-derived nanovesicles have been loaded
with various chemotherapeutic agents and demonstrated to track to the tumor
13

microenvironment in vivo, resulting in decreased tumor growth without the adverse
effects associated with administration of free drug (74).
The ability of macrophages to directly affect angiogenesis prompted us to
specifically consider the role of macrophages in adaptive resistance to VEGF
blockade. Given the clinical significance of adaptive resistance to anti-VEGF
therapy, the biological roles and underlying mechanisms by which macrophages
contribute to adaptive resistance to anti-VEGF therapy are the focus of the present
study.

14

Hypotheses and Specific Aims
The overall hypotheses of this project are:
1) Depletion of macrophages in the tumor microenvironment will alter adaptive
tumor responses and improve the efficacy of anti-VEGF therapy.
2) Prolonged exposure to anti-VEGF therapy results in down-regulation of VEGF
receptors on macrophages, allowing them to persist in the microenvironment and
aid tumor growth through the release of pro-angiogenic factors.

These hypotheses can by pictorially unified into a central hypothesis, seen in Figure
1. Tumors are initially responsive to anti-VEGF therapy, where treatment is
associated with a reduction both macrophage infiltration and tumor growth. With
prolonged treatment and the development of resistance, macrophage infiltration
increases, with a reduction in VEGFR expression. During this phase, tumor growth
rapidly increases through the liberation of other macrophage-derived pro-angiogenic
factors. The following specific aims will test this hypothesis:
Specific Aim 1: To determine the biological role of macrophages in adaptive
resistance to anti-VEGF therapy
Specific Aim 2: To identify the mechanisms by which macrophages
contribute to adaptive resistance to anti-VEGF therapy.

15

Figure 1. Central Hypothesis. VEGFR-expressing (green) and VEGFR-negative
(red) macrophages are found in the tumor microenvironment. The initiation of antiVEGF therapy reduces both tumor size and macrophage infiltration. In this phase,
macrophages expressing VEGFR predominate. With continued anti-VEGF therapy,
resistance emerges and VEGFR-negative macrophages are found in abundance in
the microenvironment.
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Methods
Cell lines and tissue culture
IG10 cells were maintained in DMEM-F12 supplemented with 5% fetal
bovine

serum,

1x

insulin-transferrin-sodium

selenite

supplement

(Roche

Diagnostics, Indianapolis, IN), and 0.1% gentamicin sulfate (Gemini Bioproducts,
Calabasas, CA). OVCAR5 was maintained in DMEM with 10% fetal bovine serum,
and 0.1% gentamicin sulfate. SKOV3ip1 was maintained in RPMI 1640
supplemented with 15% fetal bovine serum and 0.1% gentamicin sulfate. All cell
lines were routinely screened for mycoplasma and experiments were performed at
60-80% cell confluence.
Immortomouse macrophages
Immortomouse macrophages, a kind gift from Dr. Robert Langley, were
maintained in DMEM with 10% fetal bovine serum, and 0.1% gentamicin sulfate.
These conditionally immortalized cells are derived from the immortomouse (Jackson
Laboratory, Bar Harbor, ME)

and bear a transgene which allows interferon-

inducible expression of a thermolabile large tumor antigen (TAg) (and the small
tumor antigen) from the SV40 thermosensitive A58 (tsA58) strain directed to
widespread tissues by the interferon-inducible Class I antigen promoter from the
mouse H-2Kb locus. The tsA58 TAg gene product is functional at the 33°C, but is
rapidly degraded at 39.5°C (75). In this way, immortomouse macrophages could be
cultured at 33°C, where they proliferate as an immortalized cell line, but fail to
proliferate after incubation at 39.5°C.
Animal studies
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All animal work was done in accordance with protocols approved by the MD
Anderson Institutional Animal Care and Use Committee.

Female athymic nude

mice and immune competent (C57BL/6) mice were purchased from the Animal
Production Area of the National Cancer Institute-Frederick Cancer Research and
Development Center (Frederick, MD). All animals were cared for in accordance to
the guidelines set forth by the American Association for Accreditation of Laboratory
Animal Care and the US Public Health Service policy on Human Care and Use. All
animals used were 8-12 weeks old at the time of injection.
In vivo model of ovarian cancer and tissue processing
For all animal experiments, cells were harvested using trypsin-EDTA,
neutralized with FBS-containing media, washed, and re-suspended to the
appropriate cell number in HBSS prior to injection. IG10 (1x106) cells were
transduced with lentivirus-encoding luciferase and injected into C57BL/6 mice. Mice
were imaged once weekly for luminescent signals using a Xenogen IVIS system.
For syngeneic experiments, B20 mAb, a murine monoclonal VEGF-A and VEGFR-2
antibody (Genentech Inc, San Francisco, CA) was administered intraperitoneally at
5mg/kg, twice weekly. For nude models, bevacizumab was given intraperitoneally at
6.25 mg/kg, twice per week. Zoledronic acid was given intraperitoneally at 1 mg/kg,
once weekly. At the time of necropsy, the weight, number, and distribution of tumors
were recorded. Individuals who performed necropsies were blinded to the treatment
group assignments. Tissue specimens were fixed with either formalin or optimal
cutting temperature compound (OCT) (Miles, Elkhart, IN), or snap frozen in liquid
nitrogen.
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Quantitative real-time PCR
The total RNA from either cell lines or tumor tissue was extracted using a
Qiagen RNeasy Kit (Qiagen, Valencia, CA). Using 1 µg of RNA, cDNA was
synthesized using a Verso cDNA kit (Thermo Scientific, Houston, TX) per the
manufacturer's instructions. cDNA was then subjected to amplification by real-time
PCR using specific primer sequences (100 ng/µL) as specified in Table 2. For realtime RT-PCR, we obtained quantitative values (each sample was normalized on the
basis of its 18S content) as previously described (76).
Table 2. PCR primer sequences.
Gene
Forward Sequence
VEGFR1 5’-CGGAAGGAAGACAGCTCATC-3’
VEGFR3
5’-CCCCGGTGTCAATCACATA-3’

Reverse Sequence
5’-CTTCACGCGACAGGTGTAGA-3’
5’-CTCTGCCTCGGACTCCTC-3’

Methylation-specific PCR
MethPrimer software (http://www.urogene.org/methprimer/) was used for the
prediction of the CpG islands of the murine VEGFR1 promoter regions and for
design of methylation-specific primers. CpG islands of the promoter are seen in
Figure

2.

Figure 2. VEGFR-1 promoter CpG islands. VEGFR-1 promoter CpG islands are
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shown above, as predicted using MethPrimer software. Actual CpG sequences are
shown along the bottom as red dashes.
Using

this

software,

appropriate

primers

were

designed

(VEGFR1

methylated sense: 5’- GGAGTTTGTAAGGATTTTTTGAGC-3’, VEGFR1 methylated
antisense:
sense:

5’-

5’- CGACACCTCCTTCTAATAACGTC-3’,

VEGFR1

un-methylated

GGAGTTTGTAAGGATTTTTTGAGTG-3’,

VEGFR1

un-methylated

antisense: 5’- CCAACACCTCCTTCTAATAACATC-3’. Total DNA was isolated from
control, AVA sensitive, and AVA resistant immortomouse macrophages cells using
Phenol:Chloroform extraction, followed by treatment with bisulphite using a
methylation kit (EZ DNA Methylation-Gold; Zymo Research, Orange, CA). Using
real-time PCR, as described above, quantification of methylation in AVA resistant
samples was compared to AVA sensitive samples.
Immunoblotting
For immunoblotting, lysates from cultured cells were prepared using modified
RIPA buffer (50 mM Tris–HCl [pH 7.4], 150 mM NaCl, 1% Triton, 0.5%
deoxycholate) plus 25 µg/mL leupeptin, 10 µg/mL aprotinin, 2 mM EDTA, and 1 mM
sodium orthovana. Protein concentrations were determined using a BCA Protein
Assay Reagent kit (Pierce Biotechnology, Rockford, IL). Lysates were loaded and
separated on 8% sodium dodecyl sulfate—polyacrylamide gels. Proteins were
transferred to a nitrocellulose membrane by semidry electrophoresis (Bio-Rad
Laboratories, Hercules, CA) overnight, blocked with 5% milk for 1 hour and then
incubated at 4°C with primary antibody overnight. After washing with TBST, the
membranes were incubated with horseradish peroxidase (HRP)—conjugated horse
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anti-mouse IgG (1:2000, GE Healthcare, UK) for 2 hours. HRP was visualized by
use of an enhanced chemiluminescence detection kit (Pierce). To confirm equal
sample loading, the blots were probed with an antibody specific for beta-Actin (0.1
µg/mL; Sigma). Densitometric analysis was performed using ImageJ.
Gene Expression Microarray
Immortalized murine macrophages were treated with AVA for 2 weeks (antiVEGF sensitive) and 6 weeks (anti-VEGF resistant) then RNA was extracted using
mirVana RNA isolation labeling kit (Ambion, Grand Island, NY). Five hundred
nanograms of total RNA were used for labeling and hybridization on a MurineWg-6
v2 Beadchip (Illumina, San Diego, CA) according to the manufacturer’s protocol.
After the bead chips were scanned with an Illumina BeadArray Reader (Illumina),
the microarray data were normalized using the quantile normalization method in the
Linear Models for Microarray Data (LIMMA) package in the R language
environment. The expression level of each gene was transformed into a log2 base
before further analysis.
Reverse Phase Protein Arrays (RPPA)
Immortalized murine macrophages were treated with AVA for 2 weeks
(sensitive) and 6 weeks (resistant). Cells were harvested at 80% confluence and
lysed in modified radioimmunoprecipitation assay (RIPA) buffer (50 mmol/L Tris,
150 mmol/L NaCl, 1% Triton X-100, 0.5% deoxycholate, 25 µg/mL leupeptin, 10
µg/mL aprotinin, 2 mmol/L EDTA, and 1 mmol/L sodium orthovanadate). RPPA
analysis was performed at the University of Texas, M.D. Anderson Cancer Center
RPPA Core Facility using the methods described at the following web address:
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http://www.mdanderson.org/education-and-research/resources-forprofessionals/scientific-resources/core-facilities-and-services/functional-proteomicsrppa-core/index.html. Samples were probed with 161 antibodies by CSA
amplification approach and visualized by DAB colorimetric reaction. Slides were
scanned on a flatbed scanner to produce a 16-bit TIFF image. Spots from TIFF
images were identified and the density was quantified by MicroVigene. Relative
protein levels for each sample were determined by interpolation of each dilution
curves from the "standard curve" (supercurve) of the slide (antibody). All data
presented is in fold-change compared to the baseline (control treatment). Positive
fold-change was calculated by dividing each linear value (>1.0) with average control
linear value for each antibody tested, while negative fold-change (for linear values
<1.0) was also calculated (using the following formula: [-1/linear fold-change]) as in
log 2.0 value.
Cytokine Assay
Supernatant from cultured control, AVA sensitive and AVA resistant murine
macrophages were stored at −20°C for batch analyses to measure cytokines.
Supernatants were evaluated for cytokines/chemokines using the Milliplex MAP
murine cytokine/chemokine panel (Millipore, MA). Cytokine levels were measured in
50 µL of supernatant by Multiplex cytometric bead array (Multiplex) assay on a
Luminex 100 Analyzer (Luminex Corp., Austin, Texas). The inter-variability for all
inflammatory cytokines tested was less than 10%, indicating the highly reliability of
the Multiplex-Luminex method of cytokine assay.
Migration and invasion assays
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Modified Boyden chambers (Coster, Boston, MA) were coated with 0.1%
gelatin (migration) or extracellular matrix components (invasion). Untreated, AVA
sensitive and AVA resistant immortomouse macrophages cells were suspended in
100 µL of serum-free media following one hour of exposure to AVA and added into
the upper chamber. Complete media for cells containing 10% FBS (500 µL) was
added to the bottom chamber as a chemo-attractant. The chambers were incubated
at 37°C in 5% CO2 for 6 hours (migration) or overnight (invasion). After incubation,
cells were fixed, stained, and counted in 5 random fields using light microscopy at
200x.
Cell Viability Assay
Immortalized murine macrophages sensitive and resistant to AVA therapy (1
x 104 in 100 µL) were plated in a 96-well plate.

After 24 hours, 3-(4,5-

dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide or MTT, was added to each
well. The plate was incubated at 37°C for 20 minutes and then absorbances were
read at 570 nm (Ceres UV 900C; Bio-Tek Instrument Inc, Winooski, VT).
Immunostaining
All staining was performed in formalin-fixed, paraffin-embedded 8-µm thick
tumor

sections

or

OCT-embedded

frozen

tissue

sections.

Following

deparaffinization, rehydration, and antigen retrieval or fixation, 3% H2O2 was used
to block endogenous peroxidase activity for 10 minutes. Protein blocking of nonspecific epitopes was done using either 5% normal horse serum, 1% normal goat
serum, or 4% fish gelatin in either PBS or TBS-T for 20 minutes. Slides were
incubated with primary antibody for CD68 (Santa Cruz, 1:400), VEGFR1 (AbCam,
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1:500), CD-31 (Pharmingen, 1:800 for mouse tissue), overnight at 4 ºC. For
immunohistochemistry, after primary antibody was washed with PBS, the
appropriate amount of horseradish peroxidase-conjugated secondary antibody was
added and visualized with 3,3’-diaminobenzidine chromogen and counterstained
with Gill’s hematoxylin #3. For immunofluorescence, secondary antibody staining
was performed with either Alexa 594 or 488 (Molecular Probes). Nuclear staining
was performed with Hoechst 33342 (1:10,000; Molecular Probe H3570). Light field
images were obtained using a Nikon Microphot FXA microscope and Leica DFC320
digital camera, and immunofluorescent images were obtained using a Zeiss
Axioplan 2 microscope and Hamamatsu ORCA-ER digital camera. To quantify
microvessel density, we examined 5-10 random fields at 100x magnification for
each tumor (5 tumors per group) and counted the microvessels within those fields
as previously described (77). A vessel was defined as an open lumen with at least
one adjacent CD31-positive cell. Multiple positive cells beside a single lumen were
counted as one vessel. Quantification was performed by two investigators in a
blinded fashion. For immunofluorescent quantification, VEGFR1 expression was
determined using Photoshop by calculating the mean pixel density for each
representative image.
Statistical analysis
Differences in continuous variables such as tumor weight were analyzed
using the Mann-Whitney rank sum test. Two-tailed P values of no more than 0.05
were deemed statistically significant. Normally distributed continuous variables were
compared using the student t-test. Differences in variables that were not normally
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distributed were compared using a nonparametric test (Mann-Whitney U test). Only
two-tailed values are reported in this study. We considered P values less than 0.05
to be significant. Statistical analysis of the clinical data was performed using 2sample t-test and Fisher’s exact test. Survival analysis was performed using
Kaplan- Meier analysis.
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Results
Macrophage numbers increase with development of anti-VEGF resistance
To evaluate the role of immune cells in the development of resistance to
VEGF blockade, we first established a syngeneic mouse model of anti-VEGF
resistance. After intraperitoneal injection of luciferase-labeled IG10 ovarian cancer
cells and following confirmation of tumor establishment with bioluminescence
imaging, immune competent C57BL/6 mice were randomized to two treatment
groups: 1) control and 2) Anti-VEGF antibody (AVA). Treatment mice received AVA
twice weekly and both groups underwent weekly bioluminescence imaging to
monitor tumor growth. Mice receiving AVA were subsequently divided into AVAsensitive or AVA resistant groups based on imaging. AVA resistant mice were
defined as those with increased tumor growth, by increased bioluminescence
intensity in previously stable tumor burden (Figure 3). This point marked clinical
resistance to anti-VEGF therapy. All mice were subsequently sacrificed and tumors
collected for immune cell profiling.
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Figure 3. Establishment of a model of AVA resistance. Following injection of
luciferase-labeled IG10 cells, AVA treatment was initiated and continued until
increased tumor burden was demonstrated by bioluminescence imaging.

Immune cells were isolated from the collected tumors of control, AVAsensitive, and AVA-resistant mice then subjected to FACS profiling. Compared to
control samples, tumors from AVA-sensitive mice showed decreased macrophage
infiltration. In contrast, macrophages were increased in the tumors of AVA-resistant
mice, while other immune cell populations remained unchanged (p<0.0001, Figure
4).

27

Figure 4. FACS myeloid cell profiling of tumor samples. (A) Myeloid cells were
isolated from tumor samples of control, AVA sensitive, and AVA resistant groups
and sorted by flow-assisted cytometry according to CD11b+F4/80+ expression. (B)
The proportion of macrophage is expressed as a percentage of the total CD45+
cells. **** indicates p<0.0001.

Additionally, tumors from AVA-resistant mice showed increased vessel
density compared to either control or AVA-sensitive tumors, as measured by CD31
staining (p<0.001, Figure 5a, b). The marked increase in macrophages seen in
coordination with increased blood vessel density lead us to consider macrophages
as potential catalysts in resistance to anti-VEGF therapy.
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Figure 5. CD31 Counts in AVA sensitive and resistant tumors. Representative
tumor sections are seen in at 200x magnification (A) with associated CD31 vessel
density counts seen in (B). *** indicates p<0.001.

Depletion of macrophages at the time of anti-VEGF resistance restores sensitivity
As anti-VEGF resistance was associated with a significant increase in tumor
macrophages in our model, we next investigated effects of their depletion using
bisphosphonates at the emergence of resistance.

Bisphosphonates, such as

zoledronic acid and clodronate, are clinically approved for the treatment of
osteoporosis and bony metastases, but also induce macrophage depletion (78-80).
(Figure 6)

29

Figure 6. CD68 staining of tumor sections after treatment with zoledronic
acid. Representative SKOV3ip1 tumor sections of control and zoledronic acidtreated tumors are shown following CD68+ immunohistochemical staining.
Magnification is at 400x. *** indicates p<0.001.

C57Bl/6 mice were again injected with luciferase-labeled IG10 ovarian
cancer cells. Following bioluminescence imaging to confirm establishment of tumor,
mice were randomized to: 1) control; 2) AVA only; or 3) AVA plus zoledronic acid.
Controls received placebo until becoming moribund and were then sacrificed.

In

the AVA only group, treatment continued twice weekly until resistance developed,
with sacrifice as mice became moribund. In the AVA or plus zoledronic acid group,
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mice received anti-VEGF therapy alone until resistance was documented, as
measured by an increase in previously stable disease burden by bioluminescence
imaging. At the emergence of resistance, weekly zoledronic acid was added to antiVEGF treatment (Figure 7).

Figure 7. Treatment schema of resistance model with zoledronic acid. Mice
received intraperitoneal injection of luciferase-labeled IG10 cells. Twenty-one days
later, mice were assigned to either AVA alone or AVA with the addition of zoledronic
acid at the emergence of resistance, as demonstrated by bioluminescence imaging.

The combined treatment was then continued until mice became moribund.
The addition of zoledronic acid at the emergence of resistance halted tumor growth
and significantly prolonged survival, as compared to either control or anti-VEGF
therapy only (p<0.001, Figure 8).
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Figure 8. Overall survival following treatment with zoledronic acid. Following
intraperitoneal injection of luciferase-labeled IG10 cells, treatment was initiated per
the treatment schema described and continued until mice became moribund. ***
indicates p<0.001.

Macrophage depletion increases the effectiveness of anti-VEGF therapy
In light of our data implicating macrophages in the development of resistance
to VEGF blockade, we investigated the upfront combination of macrophage
depletion with anti-VEGF therapy. Nude mice were injected with either SKOV3ip1
or OVCAR5 and then assigned to receive: 1) no treatment; 2) AVA only; 3)
zoledronic acid only; or 4) AVA plus zoledronic acid. Mice were sacrificed when any
group became moribund and tumors were harvested. The combination of AVA plus
zoledronic acid dramatically reduced tumor weight and nodules in both the
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SKOV3ip1 (p<0.0001 and p<0.05, Figure 9a) and OVCAR5 models (p<0.0001 and
p<0.05, Figure 9b).

Figure 9. Zoledronic acid increases the effectiveness of AVA therapy. Total
tumor weight and number of nodules are shown in SKOV3ip1 and OVCAR5 ovarian
cancer models following treatment with AVA, zoledronic acid, or the combination.
**** indicates p<0.0001, * indicates p<0.05.
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To ensure that our results were not specific to zoledronic acid, we repeated
the experiment using an additional bisphosphonate, clodronate. Nude mice were
injected with SKOV3ip1 and then randomly assigned to: 1) no treatment; 2) AVA
only; 3) clodronate only; or 4) AVA plus clodronate. Again, the combination of AVA
plus clodronate significantly reduced tumor growth (weight p<0.0001, nodules
p<0.01, Figure 10).

Figure 10.

Clodronate increases the effectiveness of AVA therapy.

Total

tumor weight and nodules are shown following treatment with clodronate, AVA, or
the combination. **** indicates p<0.0001, *** indicates p<0.01.

Additionally, the combination groups demonstrated significantly reduced
macrophage numbers as compared to the other groups (zoledronic acid p<0.0001,
clodronate p<0.001, Figure 11a-d). This decrease in macrophage infiltration mirrors
the results seen in anti-VEGF sensitive tumors in our initial immune profiling.
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Figure 11. Immunohistochemical staining of macrophages. Macrophages from
SKOV3ip1 tumor samples treated with either zoledronic acid (A), or clodronate (B),
were stained for CD68+ and numbers compared between respective groups (C, D).
Graphs represent the mean number of macrophages per 5 randomly selected 400x
high power fields (HPF) ± SEM (A) or per 5 randomly selected 200x high power
fields (HPF) ± SEM (C). Representative photomicrographs of macrophage density
are shown following treatment with zoledronic acid (A) or clodronate (B). ****
indicates p<0.0001, *** indicates p<0.001.

35

Anti-VEGF resistant macrophages display increased viability
Given the marked differences in macrophage infiltration in the AVA sensitive
and resistant settings, we wondered whether these observations may be reflective
of two distinct populations of macrophages. To investigate phenotypic differences
between AVA sensitive and resistant macrophages that might contribute to
resistance, we compared cell viability using an MTT assay. Following exposure to
either two weeks (anti-VEGF sensitive) or six weeks (anti-VEGF resistant) of AVA
treatment,

macrophages

were

exposed

to

3-(4,5-dimethylthiazol-2-yl)-2,5-

diphenyltetrazolium bromide (MTT) and cell viability was assessed. As compared to
anti-VEGF sensitive macrophages, resistant macrophages demonstrated a 57%
increase in cell viability (p<0.001, Figure 12).
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Figure 12. Viability is increased in AVA resistant macrophages. MTT assays
were performed on untreated, AVA sensitive, and AVA resistant macrophages. ***
indicated p<0.001.

Invasion/migration of anti-VEGF resistant macrophages not affected by anti-VEGF
treatment
On the basis of the increased macrophages seen at the emergence of
resistance, we wondered if AVA resistant macrophages were better adapted to
invade and migrate despite AVA therapy. To address this question, we investigated
differences in the ability of anti-VEGF sensitive and resistant macrophages to
invade and migrate following exposure to an anti-VEGF agent. Both groups were
exposed to AVA for one hour before being plated into modified Boyden chambers.
Migration and invasion were subsequently assessed at 6 hours and 24 hours,
respectively. As predicted, AVA-sensitive macrophages displayed significantly
inhibited migration following exposure to AVA (121 vs 91.4 cells per HPF, p<0.001).
In contrast, the ability of AVA-resistant macrophages to migrate was increased by
57% after exposure to AVA.

(p<0.001, Figure 13a).

While there was a trend

towards decreased invasion of AVA-sensitive macrophages following exposure to
AVA, this difference was not significant. Invasion of AVA-resistant macrophages
was not affected by AVA exposure (Figure 13b).
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Figure 13. Invasion and Migration Assays. Control, AVA-sensitive, AVAresistant macrophages were exposed to AVA treatment for one hour and then
plated into modified Boyden chambers to assess (A) migration (6 hours) and (B)
invasion (24 hours). Cell numbers per high power field (HPF, 200x) were then
counted. *** indicates p<0.001.

Anti-VEGF resistant macrophages secrete alternative pro-angiogenic cytokines
To assess phenotypic differences between anti-VEGF sensitive and resistant
macrophages, we performed a cytokine array.

Supernatant was collected from

murine macrophages exposed to either two weeks (AVA sensitive) or six weeks
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(AVA resistant) of AVA treatment and evaluated for cytokines/chemokines using the
Milliplex MAP murine cytokine/chemokine panel (Millipore, MA). Compared to antiVEGF sensitive macrophages, those resistant to VEGF blockade secreted
significantly less VEGF and instead show a trend toward increased G-CSF and
dramatically increased levels of the pro-angiogenic platelet-derived growth factor-aa
(Figure 14).

Figure 14. Cytokine array of AVA sensitive and resistant macrophages.
Cytokines altered are shown above. Significant differences are indicated. *
indicates p<0.05, *** indicates p<0.001.

High throughput analyses reveal changes in VEGFR expression
Given the significant differences in macrophage numbers in the anti-VEGF
sensitive and resistant settings, we sought to investigate the genotypic differences
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in these populations. Macrophages were cultured in vitro and treated with AVA
twice weekly. Based on our previous in vivo studies, macrophages were collected
at two weeks and six weeks to reflect anti-VEGF sensitive and resistant conditions,
respectively, and gene expression profiling was performed on isolated RNA.
Pathway enrichment analysis revealed upregulation of pro-angiogenic pathways,
including the molecules shown below (p<0.00007, Figure 15).

Figure 15. Pro-angiogenic genes upregulated in AVA resistant macrophages.
Netwalker© software was used to analyze pathways up- and downregulated in AVA
treated macrophages.

Pro-angiogenic pathways were found to be significantly

upregulated.

Concurrently,

we

also

analyzed

differences

between

macrophage

populations in the anti-VEGF sensitive and resistant conditions using reverse phase
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protein array (RPPA). Macrophages were harvested and protein extracted following
2 weeks (anti-VEGF sensitive) and 6 weeks (anti-VEGF resistant) of treatment with
AVA in vitro. Analysis revealed upregulation of anti-apoptotic pathways including
proteins such as CAV1, CTNNB1, ESR1, AKT1, MCL1, BCL2, MDM2, MAPK8,
BAX, GSK3B, BCL2L1, IGF1R, and CDKN1A (Tables 3,4; Figure 16).
Table 3. Associated functions of proteins significantly altered in RPPA

Table 4. Expanded table of RPPA network functions
Functional Annotation

negative regulation of apoptosis

negative regulation of programmed
cell death

Number of
occurrences

13

13

p-value

Genes

3.77E-14

CAV1, CTNNB1, ESR1, AKT1,
MCL1, BCL2, MDM2, MAPK8,
BAX, GSK3B, BCL2L1, IGF1R,
CDKN1A

4.06E-14

CAV1, CTNNB1, ESR1, AKT1,
MCL1, BCL2, MDM2, MAPK8,
BAX, GSK3B, BCL2L1, IGF1R,
CDKN1A
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negative regulation of cell death

13

7.18E-14

CAV1, CTNNB1, ESR1, AKT1,
MCL1, BCL2, MDM2, MAPK8,
BAX, GSK3B, BCL2L1, IGF1R,
CDKN1A

anti-apoptosis

10

9.60E-13

CAV1, CTNNB1, ESR1, AKT1,
MCL1, BCL2, BAX, BCL2L1,
IGF1R, CDKN1A

induction of apoptosis

10

6.22E-11

MAPK1, AKT1, BCL2, ETS1,
MAPK8, BAX, BCL2L1, DIABLO,
CDKN2A, CDKN1A

induction of programmed cell death

10

6.58E-11

MAPK1, AKT1, BCL2, ETS1,
MAPK8, BAX, BCL2L1, DIABLO,
CDKN2A, CDKN1A

regulation of binding

9

5.39E-10

CAV1, MAPK1, AKT1, RB1,
BCL2, MAPK8, BAX, GSK3B,
CDKN2A

transcription factor binding

9

2.54E-10

CTNNB1, ESR1, MAPK1, RB1,
BCL2, ETS1, GSK3B, PARP1,
CDKN2A

regulation of protein localization

8

4.84E-10

CTNNB1, AKT1, RB1, BCL2,
MAPK8, GSK3B, BCL2L1,
CDKN2A

cellular response to hormone stimulus

8

8.93E-09

SHC1, PXN, ESR1, MAPK1,
AKT1, EIF4EBP1, PARP1,
IGF1R

cellular response to endogenous
stimulus

8

1.65E-08

SHC1, PXN, ESR1, MAPK1,
AKT1, EIF4EBP1, PARP1,
IGF1R

response to peptide hormone
stimulus

8

1.57E-08

SHC1, PXN, MAPK1, AKT1,
EIF4EBP1, BCL2, PARP1,
IGF1R

induction of apoptosis by intracellular
signals

7

1.87E-12

AKT1, BCL2, MAPK8, BAX,
BCL2L1, DIABLO, CDKN1A

interphase

7

2.63E-07

AKT1, RB1, EIF4EBP1, BCL2,
MDM2, CDKN2A, CDKN1A
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Figure 16. Proteins significantly altered in AVA resistant macrophages.
Proteins either significantly up- or downregulated are shown. Netwalker© software
was used to create networks of related molecules.

Decreased macrophage VEGFR-1 expression with resistance to anti-VEGF therapy
In the context of therapy directed at the VEGF pathway, we investigated
whether VEGFR expression changes could be modulating the differences in
behavior observed between AVA sensitive and resistant macrophages.

We

assessed the effects of AVA therapy on macrophage VEGF receptor expression in
vitro. Cultured macrophages were treated with AVA twice weekly. Subsequently,
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VEGFR expression was assessed at baseline, two weeks (AVA sensitive), and six
weeks (AVA resistant). We found that, following an initial period of upregulation
during the

AVA

sensitive

phase,

VEGFR-1

expression

was

significantly

downregulated in the setting of AVA resistance (p<0.001, Figure 17). Because
VEGFR-1 expression was the most significantly altered in AVA resistant
macrophages, we chose to focus on this receptor.

Figure 17. Macrophage VEGFR expression. Macrophage VEGFR-1, VEGFR-2,
and VEGFR-3 expression were assessed in untreated, AVA sensitive and AVA
resistant macrophages.

VEGFR-1 expression was significantly altered in AVA

resistant macrophages compared to those that were AVA sensitive. *** indicates
p<0.001.
VEGFR-1 protein levels from untreated, AVA sensitive, and AVA resistant
macrophages were compared using western blot.

AVA resistant macrophages
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demonstrated significantly less protein expression of VEGFR-1, as seen in Figure
18. These results were confirmed by immunofluorescent staining (Figure 19).

Figure 18. VEGFR-1 expression by Western Blot. VEGFR-1 expression
was compared in untreated, AVA sensitive, and AVA resistant macrophages using
Western Blot. β-actin served as a loading control.
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Figure 19. Immunofluorescent staining of macrophage VEGFR-1 expression.
Following treatment with AVA, expression of VEGFR-1 was quantitated in sensitive
and resistant macrophages.

Representative micrographs are shown at 400x

magnification.

In parallel, we assessed co-localization of CD68 and VEGFR-1 in AVA
sensitive and AVA resistant tumor samples.

Again, we noted decreases in

macrophage expression of VEGFR-1 (Figure 20) in AVA resistant tumors compared
to AVA sensitive tumors.
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Figure 21. Co-localization of macrophages and VEGFR-1 in tumor samples.
Macrophage expression of VEGFR-1 was assessed in tumor samples (IG10) using
CD68+ and VEGFR-1 antibodies in AVA sensitive (top panel) and AVA resistant
(bottom panel) tumors. Representative photomicrographs are shown at 400x
magnification.

Downregulation of VEGFR-1 promoter with AVA resistance
We sought to uncover the mechanism by which macrophage VEGFR-1
downregulation occurs. Since VEGFR-1 methylation has been linked to the
expression of VEGF and as methylation is known to play a role in drug resistance
and can be induced by hypoxia, we assessed methylation of the promoter region of
VEGFR-1 following AVA treatment, a known generator of hypoxia (81-83). DNA
samples from AVA sensitive and resistant macrophages were treated with bisulphite
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and methylation-specific polymerase chain reaction (MSP) analysis was performed,
revealing a significant increase in methylation at the at the VEGFR-1 promoter
region (p<0.05, Figure 21).

Figure 21.

Relative VEGFR-1 CPG methylation.

Following treatment with

bisulphite, VEGFR-1 methylation was assessed by methylation-specific polymerase
chain reaction (MSP). * indicates p<0.05.
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Summary
This work makes several contributions to the current understanding of
resistance to AVA therapy, with important clinical implications.

1)

Increases in tumoral macrophages are associated with the emergence of

resistance to AVA therapy. The depletion of macrophages at this transition point
restores sensitivity to AVA therapy and prolongs survival in murine models. The
upfront combination of bisphosphonates with AVA therapy is synergistic in reducing
tumor growth.

2)

Prolonged AVA therapy induces adaptive changes in macrophages, with

upregulation of angiogenic and anti-apoptotic pathways, which may facilitate tumor
growth in the AVA resistant microenvironment.

3)

AVA therapy results in downregulation of macrophage VEGFR-1.

This

decreased expression of macrophage VEGFR-1 is secondary to increased VEGFR1 promoter methylation.
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Discussion
Biological significance of macrophages in anti-VEGF resistance
While macrophages have been previously implicated in the development
resistance to chemotherapy, their role in resistance to VEGF blockade is not well
studied (59, 84). Previously, targeting of the Ang/Tie2 pathway has impaired the
angiogenic activity of Tie2 expressing macrophages and diminished the emergence
of resistance in vivo (62).

In our detailed investigation into the contribution of

macrophages to anti-VEGF resistance, we first show decreased TAM infiltration in
tumors sensitive to AVA therapy. This mirrors previously published data showing
that AVA therapy can decrease tumoral macrophages (85). Next, we demonstrate,
for the first time, chronological increases in tumoral macrophages with the
emergence of resistance to anti-VEGF therapy.
This influx of macrophages has important biological significance, as
macrophages are capable of secreting numerous angiogenic factors, including
VEGF, PlGF, and others seen in Table 1(86). Indeed, in coordination with elevated
macrophage counts, we show dramatically increased blood vessel density in AVA
resistant tumors. The significance of macrophages in AVA resistance is most
dramatically illustrated by the prolonged survival of mice receiving zoledronic acid
following the emergence of resistance.

As compared to mice receiving only AVA

therapy, who all developed resistance and quickly became moribund, those mice
receiving zoledronic acid had stable or reduced disease burden and lived for up to
six months following tumor cell injection.

We also show the potential additive

combination of bisphosphonate with AVA therapy in the upfront setting. While mice
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in all groups were sacrificed when the control groups became moribund, those
receiving AVA therapy with bisphosphonates demonstrated no evidence resistance
and had very little disease burden.
Several other experiments need to be performed to definitely prove the
catalytic role of macrophages in AVA resistance. First, we are presently creating a
murine Csf1 knockout model. Homozygous mice lack Csf1, a critical growth factor
for development of the monocyte and macrophage lineage, resulting in a dramatic
reduction of systemic macrophage counts (87). Csf1op/ Csf1op mice will be injected
intraperitoneally with IG10 cells and assigned to 1) no treatment, or 2) AVA alone.
Matched groups of wild-type C57Bl/6 will also be injected with IG10 cells to serve as
additional controls.

As compared to wild-type mice, we expect Csf1op/ Csf1op mice

receiving no treatment to have a prolonged disease course, while those receiving
AVA will fail to develop resistance to VEGF blockade.
We will also investigate whether re-introduction of macrophages into our
Csf1 knockout model will restore the wild-type pattern of AVA resistance. Csf1op/
Csf1op knockout mice will be injected with IG10 cells and assigned to 1) AVA
therapy alone, or 2) AVA therapy plus macrophage transfusion. Matched groups of
wild-type C57Bl/6 will be injected with IG10 cells to serve as controls. We predict
the survival of Csf1op/ Csf1op receiving macrophage infusion therapy with AVA
therapy to recapitulate that of untreated wild-type mice. Untreated Csf1op/ Csf1op
mice should fail to develop resistance to AVA therapy.
In light of recent data suggesting that both resident and bone marrow-derived
macrophages can proliferate, the origin of influxing macrophages must be
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delineated (54). We are currently investigating whether the increase in
macrophages seen at the emergence of resistance is secondary to resident
macrophage proliferation or increased recruitment from bone marrow populations.
In this experiment, bone marrow was isolated from GFP-labeled FVB.Cg-Tg(CAGEGFP)B5Nagy/J mice. These mice express a GFP label in all tissues, including the
bone marrow and its derived cells. Following cell sorting to confirm GFP labeling,
harvested bone marrow cells were injected into irradiated wild-type C57Bl/6 mice
(n=15).

Successful bone marrow transplant will be confirmed by hematologic

profiling 4 weeks post-transplant, including verification of GFP expression in bone
marrow-derived cells. Recipient mice will then be injected with luciferase-labeled
IG10 cells and tumor establishment verified 21 days after injection.

Mice will

receive AVA therapy twice weekly in conjunction with weekly bioluminescent
imaging. Mice will be while sensitive and resistant to VEGF blockade, as
demonstrated by imaging.

Macrophages of bone marrow origin will be GFP-

labeled, while resident tissue macrophages will not be labeled, allowing them to be
distinguished. Injection with BRDU prior to sacrifice will allow us to determine if the
increase in macrophages with AVA resistance is secondary to proliferation.
Mechanisms
In this study, we prove that AVA sensitive and resistant macrophages are
phenotypically distinct. AVA resistant macrophages display increased cell viability
and increased migratory ability, as compared to their AVA sensitive counterparts.
Additionally, AVA resistant macrophages have altered cytokine secretion, with
significantly increased production of PDGF-AA and decreased VEGF. PDGF-AA is
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implicated in both the autocrine and paracrine angiogenic switch in solid tumors
(88).

To our knowledge, this is the first time a distinctly different macrophage

population has been shown to emerge in response to AVA therapy.
Additionally, we use high-throughput studies to show that pro-angiogenic and
anti-apoptotic pathways are upregulated in AVA resistant macrophages.

While

many studies have focused on tumor cell adaptation to AVA therapy, this is the first
to specifically show macrophage adaptation to AVA therapy.

Collectively, we

believe these changes allow macrophages to continue to aid tumor growth in the
face of AVA therapy, where they might otherwise be depleted.
We demonstrate modulation of macrophage VEGFR-1 in response to AVA
therapy. The reduction in expression of macrophage VEGFR-1 is secondary to
increased VEGFR-1 promoter methylation.

Promoter methylation is a known

mechanism for drug resistance (89, 90). We are currently exposing AVA resistant
macrophages to the de-methylating agent, azacitidine. Restoration of AVA
sensitivity would support VEGFR-1 methylation as a mechanism of drug resistance
in macrophages.
Macrophage VEGFR-1 expression has also been linked to phenotypic
behavior, as antibody blockade of VEGFR-1 reduces monocyte and macrophage
VEGF-induced migration (91, 92). It is possible that macrophage VEGFR-1 is
downregulated in response to an AVA therapy-induced reduction of VEGF levels in
the microenvironment.
Other potential explanations for decreased macrophage VEGFR-1 exist. Our
observed effect could be in response to hypoxia, which is known to be induced by
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AVA therapy (93). Previous data from our laboratory shows that AVA therapy leads
to hypoxia and increased EZH2 expression (94).

EZH2 decreases vasohibin 1

(VASH1), leading to increased angiogenesis. Data not published in our original
study also demonstrates a reduction in VEGFR-1 in response to increased EZH2
levels. We currently have several experiments underway to determine if hypoxia
alone can downregulate macrophage VEGFR-1. Together these experiments will
elucidate the complete mechanisms responsible for the VEGFR-1 reduction
described in this work.
Clinical implications
Our study has important clinical implications.

We show depletion of

macrophages at the emergence of anti-VEGF resistance using bisphosphonates
can halt tumor growth and prolong survival in murine models. Additionally, the
combination of bisphosphonates plus anti-VEGF therapy can prevent the
development of resistance and improve the effectiveness of anti-angiogenic
therapy.
These findings offer direct support to previous clinical observations regarding
the tumor-modifying ability of bisphosphonates, which have been shown to reduce
bone metastasis in breast cancer patients, and in those with prostate or renal cell
carcinoma and pre-existing bone metastasis, result in a trend towards increased
survival (64, 66).

As further evidence, we investigated the effects of

bisphosphonate use on overall cancer mortality using the Federal Drug
Administration (FDA) Adverse Event Reporting System. Of approximately 17,000
patients with a cancer diagnosis co-medicated with a bisphosphonate, overall
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reported death rate was 36% lower (17.6% vs 27.7%, p<0.0001) than those not
receiving bisphosphonates, seen below in Figure 23.

Additionally, we are in the

process of obtaining IRB approval to investigate outcomes of cancer patients
receiving bisphosphonates at M.D. Anderson Cancer Center.

Figure

22.

Overall

bisphosphonates.

mortality

in

cancer

patients

co-medicated

with

Using the FDA Adverse Event Reporting System, 191,387

cancer patients who did not receive bisphosphonates and 16,952 patients comedicated with a bisphosphonate were identified. Overall mortality is shown above
as a percentage as a percentage of each group. *** indicates p<0.0001.

Given the role of macrophages in resistance to VEGF blockade, strategies to
modify macrophage response should be investigated in combination with anti-VEGF
therapy in patients. Possible approaches include bisphosphonates, as described
here, CSF-1 inhibitors, CCR2 inhibitors, and trabectedin (67, 70, 71). Consideration
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should be given to the upfront combination of these therapies with VEGF blockade,
thereby diminishing the opportunity of macrophages to contribute to anti-VEGF
resistance. Our group is in the preliminary stages of trial design to investigate the
use of bisphosphonates or a CSF-1 inhibitor, AC708 (Ambit Biosciences; San
Diego, CA), in patients initially responsive to bevacizumab. A detailed treatment
schema is seen below in Figure 24.

Figure 23.

Proposed trial design to investigate macrophage depletion in

combination with bevacizumab. Patients initially responsive to bevacizumab will
be randomized to receive either a bisphosphonate or a CSF-1 inhibitor, AC708.

Additionally, we are investigating macrophage VEGFR-1 expression as a
potential as a predictor of response to AVA therapy.

We have obtain human
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ovarian cancer samples from patients treated with bevacizumb and are currently
performing inmmunohistochemical staining to assess

VEGFR-1 expression in

macrophages. We will then retrospectively correlate this with patients’ response to
bevacizumab treatment. We predict that patients with low macrophage VEGFR-1
expression will have diminished bevacizumab efficacy compared to those with high
macrophage VEFR-1 expression.
Limitations and Conclusions
In the current study, we demonstrate the previously unrecognized role of
macrophages in resistance to VEGF blockade.

We show that macrophage

accumulation in the tumor microenvironment correlates with the emergence of antiVEGF resistance. The downregulation of VEGFR-1 is seen in conjunction with
upregulation of alternative angiogenic and anti-apoptotic pathways, facilitating
escape from VEGF-directed therapies.
While the evidence presented in this study offers new insights into AVA
resistance, more work remains to be done to clearly elucidate the mechanisms
behind our observations. Further, bisphosphonates are known to have effects not
specific to macrophages, including decreasing endothelial cell migration and
cytokine secretion (article in press; Reusser N, et al, Clodronate Inhibits Tumor
Angiogenesis in Mouse Models of Ovarian Cancer, Cancer Biology & Therapy). As
such, the addition of a more specific method of macrophage depletion, such as a
CSF-1 inhibitor, would strengthen the evidence presented here. The use of only a
bisphosphonate at the emergence of AVA resistance, instead of AVA plus a
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bisphosphonate, should serve as an additional control and is being incorporated
into our future experiments.
In summary, we describe the previously unrecognized role of macrophages
in resistance to anti-VEGF therapy. We offer strategies to modulate the influence of
macrophages, thus improving the effectiveness of VEGF blockage. These readily
translatable findings warrant further clinical investigation.
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